Guggenheim Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $35

Benzinga · 08/04 11:52
Guggenheim analyst Debjit Chattopadhyay maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $43 to $35.